Global Liquid Biopsy Market 2017-2021

  • ID: 4143992
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
until May 31st 2018
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AccuraGen
  • CellMax Life
  • Cynvenio Biosystems
  • Genomic Health
  • Pathway Genomics
  • Sysmex
  • MORE
About Liquid Biopsy

Like prostate cancer, other cancer cases such as lung cancer and breast cancer are increasing. To treat the disease at its early stage, liquid biopsies are performed, which helps in the detection of cancer. An increasing number of cancer cases will increase the need for liquid biopsy in the market. The skilled lab technicians are required to handle liquid biopsy systems such as polymerase chain reactions (PCRs) and assays. However, shortage of skilled physicians and lab technicians is one of the major challenges in the market. Lack of skilled technicians is a common challenge in hospitals and diagnostic laboratories in many developing and underdeveloped countries in APAC and the Sub-Saharan region. This will pose a major threat, as improper testing can lead to errors in the test results.

The analysts forecast the global liquid biopsy market to grow at a CAGR of 20.31% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global biopsy market market for 2017-2021. To calculate the market size, the report considers the considers the global demand for liquid biopsy.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Liquid Biopsy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Biocept
- Exosome Diagnostics
- QIAGEN
- Roche Molecular Diagnostics

Other prominent vendors
- AccuraGen
- Agena Bioscience
- Bio-Rad Laboratories
- CellMax Life
- Chronix Biomedical
- Clearbridge BioMedics
- Circulogene Theranostics
- Cynvenio Biosystems
- Epic Sciences
- Freenome
- Genomic Health
- Natera
- Novogene
- OncoCyte
- Pathway Genomics
- Personal Genome Diagnostics
- RainDance Technologies
- Sequenom
- Sysmex
- Thermo Fisher Scientific
- Transgenomic
- Vermillion
- WaveSense

Market drivers
- Increasing prevalence of cancer cases in older population
- For a full, detailed list, view the full report

Market challenges
- Dearth of skilled professionals, laboratory technicians, and oncologists
- For a full, detailed list, view the full report

Market trends
- Venture capitalists for market entry of start-ups
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the Key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AccuraGen
  • CellMax Life
  • Cynvenio Biosystems
  • Genomic Health
  • Pathway Genomics
  • Sysmex
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Key market highlights
  • Biopsy
  • Liquid biopsy: Future of cancer diagnostics
PART 05: Market landscape
  • Market overview
  • Clinical trials
  • Market size and forecast
  • Five forces analysis
PART 06: Market segmentation by product
  • CTCs and ctDNA
  • Exosomes and RNA
PART 07: Market segmentation by end-user
  • Global liquid biopsy market by end-user in 2016
  • Hospitals
  • Clinical diagnostic laboratories
  • Physicians' office laboratories
PART 08: Geographical segmentation
  • Liquid biopsy market in Americas
  • Liquid biopsy market in US
  • Liquid biopsy market in EMEA
  • Liquid biopsy market in UK
  • Liquid biopsy market in APAC
  • Liquid biopsy market in China
PART 09: Market drivers
  • Increasing prevalence of cancer cases in older population
  • Government initiatives and pilot programs
  • Collaboration between companies for co-development of products
PART 10: Impact of drivers

PART 11: Market challenges
  • Lack of reimbursement
  • Dearth of skilled professionals, laboratory technicians, and oncologists
  • High cost of clinical trials and failure rate in clinical trials
PART 12: Impact of drivers and challenges

PART 13: Market trends
  • Focus on chip development as novel product
  • Venture capitals for market entry of start-ups
  • Direct-to-consumer laboratory testing
PART 14: Vendor landscape
  • Competitive landscape
PART 15: Key vendor analysis
  • Biocept
  • Exosome Diagnostics
  • QIAGEN
  • Roche Molecular Diagnostics
  • Key companies to watch
  • Other prominent vendors
PART 16: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Comparison: Liquid biopsy and tissue biopsy methods
Exhibit 02: Types of liquid biopsy tests
Exhibit 03: Market overview: Global liquid biopsy market
Exhibit 04: Pipeline of liquid biopsy in Americas
Exhibit 05: Pipeline of liquid biopsy in Europe
Exhibit 06: Pipeline of liquid biopsy in APAC
Exhibit 07: Global liquid biopsy market 2016-2021 ($ millions)
Exhibit 08: Global liquid biopsy potential market 2016
Exhibit 09: Market scenario: Market impact analysis of global liquid biopsy market ($ millions)
Exhibit 10: Five forces analysis
Exhibit 11: Global liquid biopsy market segmentation by product 2016
Exhibit 12: Market overview: CTCs and ctDNA
Exhibit 13: Market overview: Exosomes and RNA
Exhibit 14: Revenue generated by diagnostic and medical laboratories in US 2009-2014 ($ millions)
Exhibit 15: Global liquid biopsy market by geography 2016 and 2021
Exhibit 16: Market overview: Liquid biopsy market in Americas
Exhibit 17: New cancer cases and cancer deaths in US 2015-2020 (per 100,000 population)
Exhibit 18: Global liquid biopsy market in Americas 2016-2021 ($ millions)
Exhibit 19: Market impact analysis: Liquid biopsy market in Americas
Exhibit 20: Market overview: Liquid biopsy market in US
Exhibit 21: Market overview: Liquid biopsy market in EMEA
Exhibit 22: Global liquid biopsy market in EMEA 2016-2021 ($ millions)
Exhibit 23: Market impact analysis: Liquid biopsy market in EMEA
Exhibit 24: Market overview: Liquid biopsy market in UK
Exhibit 25: Market overview: Liquid biopsy market in APAC
Exhibit 26: Colorectal cancer mortality per 100,000 individuals in APAC 2003 and 2013
Exhibit 27: Global liquid biopsy market in APAC 2016-2021 ($ millions)
Exhibit 28: Market impact analysis: Liquid biopsy market in APAC
Exhibit 29: Market overview: Liquid biopsy market in China
Exhibit 30: Older population with cancer in US
Exhibit 31: Government initiatives for cancer and liquid biopsy testing in some countries
Exhibit 32: Market impact analysis: Collaboration between medical device and pharmaceutical companies for liquid biopsy
Exhibit 33: Impact of drivers
Exhibit 34: Number of skilled physicians per 1,000 population 2014
Exhibit 35: Impact of drivers and challenges
Exhibit 36: Market impact analysis: Focus on novel product development by institutes and companies
Exhibit 37: Collaboration of companies with venture capitalists
Exhibit 38: Competitive structure analysis of global liquid biopsy market 2016
Exhibit 39: Competitive landscape analysis of global liquid biopsy market 2016
Exhibit 40: Strategic recommendation for vendors in the global liquid biopsy market
Exhibit 41: Biocept: Key highlights
Exhibit 42: Biocept: Strength assessment
Exhibit 43: Biocept: Strategy assessment
Exhibit 44: Biocept: Opportunity assessment
Exhibit 45: Exosome Diagnostics: Key highlights
Exhibit 46: Exosome Diagnostics: Strength assessment
Exhibit 47: Exosome Diagnostics: Strategy assessment
Exhibit 48: Exosome Diagnostics: Opportunity assessment
Exhibit 49: QIAGEN: Key highlights
Exhibit 50: QIAGEN: Strength assessment
Exhibit 51: QIAGEN: Strategy assessment
Exhibit 52: QIAGEN: Opportunity assessment
Exhibit 53: Roche Molecular Diagnostics: Key highlights
Exhibit 54: Roche Molecular Diagnostics: Strength assessment
Exhibit 55: Roche Molecular Diagnostics: Strategy assessment
Exhibit 56: Roche Molecular Diagnostics: Opportunity assessment
Exhibit 57: Key companies: Global liquid biopsy market
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AccuraGen
  • CellMax Life
  • Cynvenio Biosystems
  • Genomic Health
  • Pathway Genomics
  • Sysmex
  • MORE
New Report Released: – Global Liquid Biopsy Market 2017-2021

The author of the report recognizes the following companies as the key players in the global liquid biopsy market: Biocept, Exosome Diagnostics, QIAGEN, and Roche Molecular Diagnostics

Other Prominent Vendors in the market are: AccuraGen, Agena Bioscience, Bio-Rad Laboratories, CellMax Life, Chronix Biomedical, Clearbridge BioMedics, Circulogene Theranostics, Cynvenio Biosystems, Epic Sciences, Freenome, Genomic Health, Natera, Novogene, OncoCyte, Pathway Genomics, Personal Genome Diagnostics, RainDance Technologies, Sequenom, Sysmex, Thermo Fisher Scientific, Transgenomic, Vermillion, and WaveSense

Commenting on the report, an analyst from the research team said: “New players approach venture capitalists to enter into niche markets like a liquid biopsy. These venture capitalists started realizing the significant potential of start-ups that develop innovative technologies and products in the area of cancer. This has increased the financial flow support from venture capitalists, which is accelerating the development of liquid biopsy products and is leading to the market entry of start-ups. Post registration and market approvals, venture capitalists take a share from the total revenue generated by the start-ups.”

According to the report, the Americas is the major contributor in the market. The rising older population in the Americas is one of the major factors for increased adoption of liquid biopsy tests. Aging causes the immune system of the body to deteriorate. This makes most people aged 60 and above susceptible to chronic diseases such as cancer and cardiovascular diseases. The incidence of breast cancer and colorectal cancer is increasing due to the rise in the number of older people.

Further, the report states that new players approach venture capitalists to enter into niche markets like a liquid biopsy. These venture capitalists started realizing the significant potential of start-ups that develop innovative technologies and products in the area of cancer. This has increased the financial flow support from venture capitalists, which is accelerating the development of liquid biopsy products and is leading to the market entry of start-ups. Post registration and market approvals, venture capitalists take a share from the total revenue generated by the start-ups.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Biocept
  • Exosome Diagnostics
  • QIAGEN
  • Roche Molecular Diagnostics
  • AccuraGen
  • Agena Bioscience
  • Bio-Rad Laboratories
  • CellMax Life
  • Chronix Biomedical
  • Clearbridge BioMedics
  • Circulogene Theranostics
  • Cynvenio Biosystems
  • Epic Sciences
  • Freenome
  • Genomic Health
  • Natera
  • Novogene
  • OncoCyte
  • Pathway Genomics
  • Personal Genome Diagnostics
  • RainDance Technologies
  • Sequenom
  • Sysmex
  • Thermo Fisher Scientific
  • Transgenomic
  • Vermillion
  • WaveSense
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll